Bionoid Pharma Stock Performance
| BINP Stock | USD 0.03 0.00 0.00% |
The firm shows a Beta (market volatility) of -4.16, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bionoid Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Bionoid Pharma is expected to outperform it. Bionoid Pharma right now shows a risk of 0.0%. Please confirm Bionoid Pharma treynor ratio, as well as the relationship between the semi variance and day median price , to decide if Bionoid Pharma will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bionoid Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Bionoid Pharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Bionoid |
Bionoid Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Bionoid Pharma on November 1, 2025 and sell it today you would earn a total of 100.00 from holding Bionoid Pharma or generate -100.0% return on investment over 90 days. Bionoid Pharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Bionoid, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bionoid Pharma Target Price Odds to finish over Current Price
The tendency of Bionoid Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.03 | 90 days | 0.03 | about 53.3 |
Based on a normal probability distribution, the odds of Bionoid Pharma to move above the current price in 90 days from now is about 53.3 (This Bionoid Pharma probability density function shows the probability of Bionoid Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Bionoid Pharma has a beta of -4.16 suggesting as returns on its benchmark rise, returns on holding Bionoid Pharma are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Bionoid Pharma is expected to outperform its benchmark. In addition to that Bionoid Pharma has an alpha of 2.9824, implying that it can generate a 2.98 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bionoid Pharma Price Density |
| Price |
Predictive Modules for Bionoid Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bionoid Pharma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Bionoid Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bionoid Pharma is not an exception. The market had few large corrections towards the Bionoid Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bionoid Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bionoid Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.98 | |
β | Beta against Dow Jones | -4.16 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.11 |
Bionoid Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bionoid Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bionoid Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bionoid Pharma is not yet fully synchronised with the market data | |
| Bionoid Pharma has some characteristics of a very speculative penny stock | |
| Bionoid Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Bionoid Pharma currently holds 64.5 K in liabilities. Bionoid Pharma has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bionoid Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Bionoid Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bionoid Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bionoid to invest in growth at high rates of return. When we think about Bionoid Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 92.26 K. Net Loss for the year was (1.62 M) with profit before overhead, payroll, taxes, and interest of 47.48 K. | |
| Bionoid Pharma currently holds about 127 in cash with (357.62 K) of positive cash flow from operations. |
Bionoid Pharma Fundamentals Growth
Bionoid Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bionoid Pharma, and Bionoid Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bionoid Pink Sheet performance.
| Return On Asset | -1.64 | |||
| Operating Margin | (4.22) % | |||
| Current Valuation | 3.81 M | |||
| Shares Outstanding | 42.28 M | |||
| Price To Sales | 540.76 X | |||
| Revenue | 92.26 K | |||
| EBITDA | (385.71 K) | |||
| Cash And Equivalents | 127 | |||
| Total Debt | 64.5 K | |||
| Book Value Per Share | (29.92) X | |||
| Cash Flow From Operations | (357.62 K) | |||
| Earnings Per Share | (46.27) X | |||
About Bionoid Pharma Performance
Assessing Bionoid Pharma's fundamental ratios provides investors with valuable insights into Bionoid Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bionoid Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Bionoid Pharma Inc. engages in the hemp cultivation business. Bionoid Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 5 people.Things to note about Bionoid Pharma performance evaluation
Checking the ongoing alerts about Bionoid Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bionoid Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bionoid Pharma is not yet fully synchronised with the market data | |
| Bionoid Pharma has some characteristics of a very speculative penny stock | |
| Bionoid Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Bionoid Pharma currently holds 64.5 K in liabilities. Bionoid Pharma has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bionoid Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Bionoid Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bionoid Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bionoid to invest in growth at high rates of return. When we think about Bionoid Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 92.26 K. Net Loss for the year was (1.62 M) with profit before overhead, payroll, taxes, and interest of 47.48 K. | |
| Bionoid Pharma currently holds about 127 in cash with (357.62 K) of positive cash flow from operations. |
- Analyzing Bionoid Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bionoid Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Bionoid Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bionoid Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bionoid Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bionoid Pharma's pink sheet. These opinions can provide insight into Bionoid Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bionoid Pink Sheet Analysis
When running Bionoid Pharma's price analysis, check to measure Bionoid Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionoid Pharma is operating at the current time. Most of Bionoid Pharma's value examination focuses on studying past and present price action to predict the probability of Bionoid Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionoid Pharma's price. Additionally, you may evaluate how the addition of Bionoid Pharma to your portfolios can decrease your overall portfolio volatility.